Global pharmaceutical firm Clinigen has acquired Kinesys Consulting to boost its knowledge of regulatory affairs.
The deal will fuel Burton-based Clinigen’s mission of accelerating the development and delivery of life-saving treatments to patients worldwide.
Clients will be guided by Kinesys through regulatory strategy and execution for drugs and medical devices, as well as having access to a high-quality medical/regulatory writing service
Pharmaceutical giant Clinigen was acquired by Triton Funds in 2022 in a £1.3bn deal and has since purchased Ascenian Consulting and Drug Safety Navigator.
The businesses add to Clinigen’s operations across North America, Europe, Africa and the Asia Pacific with more than 1,000 employees in 14 countries.
Kinesys team of experts will integrate into Clinigen’s Lifecycle Services division, which supports the entire drug lifecycle from development to commercialisation, including pharmacovigilance, medical information, and regulatory affairs.
Kinesys also brings a scientific and regulatory advisory board comprised of seasoned industry veterans, including former regulatory agency assessors. Clinigen says their substantial experience in drug development within the biopharmaceutical industry will be invaluable in navigating the regulatory landscape.
Jerome Charton, CEO of Clinigen said: “At Clinigen, we’re dedicated to ensuring everyone has access to the treatments they need, and this acquisition unites Clinigen’s commitment to healthcare equity with Kinesys’ specialised expertise, solidifying Clinigen’s position as a life sciences leader.
“By combining the expertise of Kinesys with our existing services, Clinigen will be better positioned to achieve our mission of accelerating the development and delivery of life-saving treatments to patients worldwide. This move underscores our commitment to helping our clients navigate the complexities of developing and commercialising drugs and medical devices, bringing innovative therapies to patients faster.”
Elaine Murphy, co-founder of Kinesys Consulting said: “At Kinesys, we specialise in guiding clients through the intricacies of regulatory strategy and execution for drugs and medical devices, as well as providing a high-quality medical/regulatory writing service. This strong foundation allows us to support our clients throughout the entire development journey. By joining Clinigen, we’re excited to offer both our existing clients and Clinigen’s a seamless path from navigating initial regulatory hurdles to achieving successful market access.”
Gerry McGettigan, co-founder of Kinesys Consulting comments: “Clinigen’s commitment to improving access to crucial treatments for patients across the globe make them the perfect partner to take Kinesys into its next exciting chapter. This partnership unlocks new horizons for Kinesys. By joining forces with Clinigen, with its leading expertise across the entire drug development landscape, we can create a truly powerful force for accelerating patient access to life-saving treatments on a global scale.”
Both Murphy and McGettigan will remain within the business to ensure a smooth transition and bring their expertise to Clinigen’s new Lifecycle Services division.
Clinigen was advised on the transaction by BDO LLP and Stevens & Bolton LLP, while Ernst and Young LLP and JMW Solicitors LLP acted as financial and legal advisors, respectively, to Kinesys Consulting.
Sourced from The Business Desk